Seer (SEER) Float Percentage Of Total Shares Outstanding : 90.81% (As of Jun. 07, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Seer Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Seer's float shares is 58.97 Mil. Seer's total shares outstanding is 64.94 Mil. Seer's float percentage of total shares outstanding is 90.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Seer's Insider Ownership is 6.48%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Seer's Institutional Ownership is 23.54%.

Seer Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Seer's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	58.97	/	64.94
	=	90.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seer (SEER) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seer Inc (NAS:SEER) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3800 Bridge Parkway, Suite 102, Redwood City, CA, USA, 94065

Website

https://www.seer.bio

Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.

Executives

Elona Esq. Kogan	officer: General Counsel and Secretary	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omid Farokhzad	director, 10 percent owner, officer: CEO and Chair of the Board	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Scott D Thomas	officer: Chief Commercial Officer	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
David R. Horn	officer: Chief Financial Officer	3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omead Ostadan	director, officer: President & COO	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Meeta Gulyani	director	C/O SEER, INC., 3800 BRIDGEPOINT PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Rachel E. Haurwitz	director	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Maverick Ventures Investment Fund, L.p.	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Capital Ventures, Llc	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Advisors Fund, L.p.	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
David Hallal	director	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Terrance Mcguire	director	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
David B Singer	director	C/O MAVERICK CAPITAL, LTD., 101 CALIFORNIA STREET, SUITE 4015, SAN FRANCISCO CA 94111
Cathy Friedman	director	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005